接受肺动静脉高压血管扩张剂治疗患者出现胰腺增大一例报告
一例肺动静脉高压患者在接受包括依前列醇在内的治疗后出现胰腺增大,但无胰腺功能异常的血检数据或胰腺炎症状,继续依前列醇治疗下腹部症状迅速改善;持续静脉输注依前列醇11个月后影像上胰腺增大仍明显,但无腹部症状或胰酶升高。本病例提示依前列醇治疗可能引起类似急性或自身免疫性胰腺炎的胰腺改变。
要点
- 肺动静脉高压患者接受依前列醇治疗后影像上可出现胰腺增大,需注意与急性或自身免疫性胰腺炎鉴别。
- 本病例胰腺增大明显但无提示胰腺功能异常或胰腺炎的血检数据及症状,继续用药下腹部症状迅速改善。
- 持续静脉输注依前列醇11个月后影像上胰腺增大仍存在,但无腹部症状或胰酶升高。
核心结论
- 依前列醇治疗可能导致类似急性或自身免疫性胰腺炎的胰腺改变。
研究设计与样本
- 病例报告;一例接受包括依前列醇在内治疗的肺动静脉高压患者。
关键影像表现/征象
- 影像上胰腺大小明显增大。
- 持续静脉输注依前列醇11个月后影像上胰腺增大仍明显。
临床应用与阅片要点
- 接受依前列醇治疗的肺动静脉高压患者影像上出现胰腺增大时,需考虑药物相关胰腺改变可能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Epoprostenol is a prostacyclin (prostaglandin I2) analog that causes vasodilation and inhibits platelet aggregation and is used in the management of severe pulmonary arterial hypertension (PAH). We herein report a patient with PAH who developed pancreatic enlargement after the initiation of therapy including epoprostenol. Although it is well known that thyroid enlargement occurs in patients with PAH receiving epoprostenol therapy, the pancreatic findings associated with epoprostenol therapy have not been well described. Although the size of the pancreas was clearly increased, there was no blood data or symptoms suggestive of abnormal pancreatic function and pancreatitis, and the patient's abdominal complaints improved quickly, despite the continuation of epoprostenol therapy. Eleven months after the start of continuous intravenous epoprostenol infusion therapy, the pancreatic enlargement was still evident on imaging, but there were no abdominal symptoms or elevated pancreatic enzymes. This case highlights the fact that epoprostenol therapy may cause pancreatic changes that mimic acute or autoimmune pancreatitis.
引用
- Someya, Koyasu, Ohnishi, et al. Pancreatic enlargement in a patient receiving therapy with vasodilators for pulmonary arterial hypertension: a case report. Abdom Radiol (NY). 2022. PMID: 35257202. doi:10.1007/s00261-022-03458-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。